You are here

New Cohort Study Begins in Mozambique

February 6, 2015
MHRP's newest site starts enrolling for RV363, which will help lay the groundwork for future vaccine trials.

MHRP recently began a new cohort study, RV363, to assess the incidence of HIV and the willingness of adults to participate in future HIV vaccine trials in Mozambique. The study will determine incidence in men and women aged 18–35 in both Maputo and Beira. 

The retention rate of the enrolled cohort will be assessed over a 2-year follow-up period with a quarterly follow-up visit. RV363 also will serve as a mechanism to further augment the clinical, laboratory, data management, quality assurance and community engagement capacity at these sites for upcoming  HIV vaccine trials. 

Subtype C is the predominant HIV subtype in Mozambique. MHRP will participate in planned HVTN-led studies in this region that will test a vaccine regimen similar to the one used in RV144 but targeted for subtype C.  These studies are part of the Pox-Protein Public-Private Partnership (P5).